September 18, 2013
The European Commission's Seventh Framework Program will award $801,360 throughout three years to scientific software company Qlucore to develop algorithms for use in personalizing hepatitis C treatment. The company will work on mathematical and statistical algorithms for integrating information from genetic, proteomic, and clinical research data to provide clinicians with a mobile application that could be used at the point of care. Pharmaceutical companies currently are developing new hepatitis C drugs that would lead to more genetic and clinical variables to evaluate for patients and create a need for tools that could assist clinicians in prescribing custom treatments for each patient.
09.16.2013; Ryan McBride
No comments have been made.
|Really Rapid Review -- AIDS 2016, Durban|
|Update on Genetic Engineering for an HIV Cure|
|Charlize Theron's 8 Quotable Moments About HIV at AIDS 2016|
|This Week in HIV Research: New Protein Could Shock and Kill Latent HIV, and Engineered T Cells Could Help Fight HIV|
|At AIDS 2016, the Global Village Rocks -- and Activists Party Without Pants|